Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by Rockefeller University
Sponsor:
Information provided by (Responsible Party):
Rockefeller University
ClinicalTrials.gov Identifier:
NCT01941537
First received: August 29, 2013
Last updated: December 16, 2014
Last verified: December 2014

August 29, 2013
December 16, 2014
October 2013
October 2017   (final data collection date for primary outcome measure)
To assess the clinical benefit as measured by SCORAD (Scoring of AD) of intravenous (IV) administration of ILV-094 administered to subjects with atopic dermatitis (AD). [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
To assess the clinical benefit, safety and tolerability of intravenous (IV) administration of ILV-094 administered to subjects with atopic dermatitis (AD). The clinical effects on AD disease activity will be evaluated by the change in the Scoring of AD (SCORAD) index and investigator's global assessment (IGA) index of AD at week 12.
Same as current
Complete list of historical versions of study NCT01941537 on ClinicalTrials.gov Archive Site
Reversal of the pathological epidermal phenotype during ILV-094 therapy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Reversal of the pathological epidermal phenotype during ILV-094 therapy, and which immune pathways are suppressed during treatment with the drug.
Same as current
Not Provided
Not Provided
 
Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Phase II Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) in Subjects With Atopic Dermatitis (AD)

Atopic dermatitis (AD) is a common inflammatory skin disorder that adversely affects most aspects of everyday life in majority of patients. It has a prevalence of up to 3-4% of adults and up to 25% among children. AD has a complex pathogenesis, characterized by: 1) immune activation with increased numbers of T-cells, dendritic cells (DCs), and increased expression of inflammatory molecules 2) marked epidermal hyperplasia in chronic diseased skin, and 3) defective barrier function with increased trans-epidermal water loss (TEWL) and decreased lipids, reflecting underlying alterations in keratinocyte differentiation. AD is predominantly a Th2 (IL-4, IL-13, and IL-31) disease, and recently was also found to be a "T22" (IL-22) polarized disease.

ILV-094 is an anti IL-22 antibody and therefore should reverse the immune activation of AD. This study is being done to assess the safety, tolerability, clinical efficacy, and mechanism of action of ILV-094 in patients with AD.

This is a randomized, double-blind, placebo-controlled, study of six IV infusions of ILV-094 administered to subjects with atopic dermatitis. Sixty subjects will be randomly assigned in a 2:1 ratio to one of the two treatments arms (ILV-094 vs placebo). Forty patients will be enrolled in the ILV-094 treatment arm and 20 in the placebo-treatment arm, accordingly. A loading IV dose of 600 mg of ILV-094 or placebo will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 or placebo every two weeks (Weeks 2, 4, 6, 8, and 10). We will continue to follow the patients every two weeks for an additional 10 weeks after the last IV dose (20 weeks post baseline).

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Atopic Dermatitis
  • Drug: ILV-094
    IV infusion of ILV-094
    Other Name: ILV-094
  • Drug: Placebo Comparator
    Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
    Other Name: Placebo
  • Experimental: ILV-094
    Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
    Intervention: Drug: ILV-094
  • Placebo Comparator: Placebo comparator
    Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
    Intervention: Drug: Placebo Comparator
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
October 2017
October 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or females between the ages 18-75 year-old, with chronic disease (>6 months).
  • Have moderate to severe AD
  • Patients who fail or cannot sustain response with one or more of the three treatment categories listed below

    • Category 1 : Hydration plus topical steroids and/or antibiotics (tetracycline, bactrim, cephalosporins, etc) and or topical immune modulators (protopic/elidel).
    • Category 2: Systemic Steroids and/or Phototherapy.
    • Category 3: Cyclosporine and/or Other Immunomodulators (Methotrexate, CellCept, and Immuran).
  • Women of childbearing potential must test negative for pregnancy and agree to use birth control measures that are highly effective.
  • Are PPD negative at the time of screening.
  • Willingness to avoid alcohol intake 48 hours before each visit in which study drug will be received, in order to avoid increases in liver function tests (LFTs) (this was an exclusion in other ILV-094 studies in order to guard against increased LFTs due to alcohol intake being attributed to study drug).

Exclusion Criteria:

  • History of active or latent serious infections (TB, or other granulomatous disorders such as histoplasmosis, coccidioidomycosis, etc). Skin colonization by Staph. aureus is expected in a high percentage of atopic patients with active disease and will not be considered as an exclusion criteria.
  • Have a known malignancy or history of malignancy (except for basal or squamous cell carcinoma completely excised without evidence of recurrence and treated carcinoma in situ of the cervix) or lymphoproliferative diseases
  • Have a nontuberculous mycobacterial infection or opportunistic systemic infection (e.g., Pneumocystis carinii, and aspergillosis) within 6 months prior to screening.
  • Have positive HIV by history or POCT on the screening visit.
  • Have documented current active hepatitis B (surface antigen positive or asymptomatic chronic carriers) or a history of hepatitis C infection (anti-HCV positive), by history and/or screening test.
  • Have a history of substance abuse (drug or alcohol) within the past year before screening.
  • Have a serious concomitant illness that could require the use of systemic corticosteroids or otherwise interfere with the patient's participation in the trial.
  • Pregnant women or women that are breast feeding or plan to breast feed.
  • Evidence of acute or unstable clinically significant disease or any unstable serious disorder requiring active frequent monitoring.
  • Evidence of other concomitant skin conditions (eg, psoriasis, or lupus erythematosus) other than atopic dermatitis that would interfere with evaluations of the effect of study medication on atopic dermatitis.
  • Use of any investigational small molecule drug within 90 days before the first dose of test article administration.
  • Have a transplanted organ (with the exception of a corneal transplant performed >3 months prior to screening).
  • Have concomitant autoimmune disease
  • Clinically important deviation from normal limits in physical examination, vital sign measurements, 12-lead electrocardiograms (ECGs), or clinical laboratory tests results, not associated with a chronic, well-controlled medical condition. Examples of these deviations include following:

    1. Undiagnosed hypertension.
    2. Evidence of undiagnosed ischemic heart disease or potentially clinically significant arrhythmia on ECG.
    3. Hemoglobin <9 g/dl
    4. WBC count < 3.5 x 109 cells/L
    5. Neutrophils <1 x 109 cells/L
    6. Platelets < 100 x 109 cells/L
    7. AST/SGOT and ALT/SGPT levels above 2 times the upper limit of normal for the laboratory conducting the test.
    8. Alkaline phosphatase levels above 2 times the upper limit of normal for the laboratory conducting the test.
  • Live vaccines within 3 months before test article administration or during the study.
Both
18 Years to 75 Years
No
Contact: Lauren Corregano 1-800-RU-CARES rucares@rockefeller.edu
Contact: Saakshi Khattri 212-327-8354
United States
 
NCT01941537
JKR-0766
Yes
Rockefeller University
Rockefeller University
Not Provided
Principal Investigator: Emma Guttman, MD The Rockefeller University
Rockefeller University
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP